Main

Prescriptions - Kamada Receives Final FDA Approval to Commence Phase III Clinical


Kamada Receives Final FDA Approval to Commence Phase III Clinical Trials of API with Congenital Emphysema Patients (Business Wire via Yahoo! Finance)
REHOVOT, Israel----March 9, 2006--Kamada , a bio-pharmaceutical company which develops, manufactures and markets prescription drugs, today announced the crossing of a major milestone on its API roadmap with the FDA announcing the removal of the "Clinical Hold" status.

Prescriptions - FDA files add to questions on limiting morning-after pill (Philly.com)


FDA files add to questions on limiting morning-after pill (Philly.com)
Internal documents made public yesterday have raised questions about the federal government's continued refusal to allow over-the-counter sales of the emergency contraceptive known as Plan B.
 
Notify me with the latest breaking FDA News
fda approvals Tell us where to send your notifications:

Prescriptions - FDA fought morning-after pill (Contra Costa Times) Records show senior


FDA fought morning-after pill (Contra Costa Times)
Records show senior government officials, while appearing neutral, worked to block approval of the "Plan B" over the counter contraceptive. Post a Comment

 

©2006 FDA-News.com. All rights reserved.